(-)-DHMEQ

(–)-DHMEQ is a potent NF-κB inhibitor.

Signaling Pathways >> NF-κB >> NF-κB

Research Areas >> Cancer

RelA

RelB

(–)-DHMEQ binds to cysteine 38 of RelA and cysteine 144 of RelB. (−)-DHMEQ at concentrations greater than 25 µM inhibits the LTβ-induced nuclear translocation of FLAG-RelB WT, whereas the inhibitory effect of (–)-DHMEQ on the nuclear translocation of FLAG-RelB (C144S) became weaker at the same concentrations[1].

A549 cells transfectants stably expressing RelB WT and RelB (C144S) are preincubated with various concentrations of (-)-DHMEQ (1, 5, 10, 25, and 50 μM) for 1h and then incubated with or without LTβ (25 ng/mL) for 2 h in the presence or absence of (-)-DHMEQ.Cytoplasmic and nuclear extracts are analyzed by Western blotting[1].

[1]. Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40(10):1669-1677.

[2]. Kang J, et al. Exposure to a combination of formaldehyde and DINP aggravated asthma-like pathology through oxidative stress and NF-κB activation. Toxicology. 2018 May 14;404-405:49-58.

BAY 11-7082 | Ammonium 1-pyrrolidinedithiocarbamate | SN50 | Triptolide | JSH-23 | Shikonine | Bay 11-7085 | Rocaglamide | Dihydroartemisinin | Tomatidine | QNZ (EVP4593) | Baicalin | Laquinimod | Parthenolide | Ginsenoside Rg3